FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2594861736> ?p ?o ?g. }

• W2594861736 endingPage "1514" @default.
• W2594861736 startingPage "1506" @default.
• W2594861736 abstract "Purpose Treating small-cell lung cancer (SCLC) remains a therapeutic challenge. Experimental studies show that statins exert additive effects with agents, such as cisplatin, to impair tumor growth, and observational studies suggest that statins combined with anticancer therapies delay relapse and prolong life in several cancer types. To our knowledge, we report the first large, randomized, placebo-controlled, double-blind trial of a statin with standard-of-care for patients with cancer, specifically SCLC. Patients and Methods Patients with confirmed SCLC (limited or extensive disease) and performance status 0 to 3 were randomly assigned to receive daily pravastatin 40 mg or placebo, combined with up to six cycles of etoposide plus cisplatin or carboplatin every 3 weeks, until disease progression or intolerable toxicity. Primary end point was overall survival (OS), and secondary end points were progression-free survival (PFS), response rate, and toxicity. Results Eight hundred forty-six patients from 91 United Kingdom hospitals were recruited. The median age of recruited patients was 64 years of age, 43% had limited disease, and 57% had extensive disease. There were 758 deaths and 787 PFS events. No benefit was found for pravastatin, either in all patients or in several subgroups. For pravastatin versus placebo, the 2-year OS rate was 13.2% (95% CI, 10.0 to 16.7) versus 14.1% (95% CI, 10.9 to 17.7), respectively, with a hazard ratio of 1.01 (95% CI, 0.88 to 1.16; P = .90. The median OS was 10.7 months v 10.6 months, respectively. The median PFS was 7.7 months v 7.3 months, respectively. The median OS (pravastatin v placebo) was 14.6 months in both groups for limited disease and 9.1 months versus 8.8 months, respectively, for extensive disease. Adverse events were similar between groups. Conclusion Pravastatin 40 mg combined with standard SCLC therapy, although safe, does not benefit patients. Our conclusions are the same as those found in all four much smaller, randomized, placebo-controlled trials specifically designed to evaluate statin therapy in patients with cancer." @default.
• W2594861736 created "2017-03-16" @default.
• W2594861736 creator A5002055690 @default.
• W2594861736 creator A5005554940 @default.
• W2594861736 creator A5016828265 @default.
• W2594861736 creator A5019646420 @default.
• W2594861736 creator A5023774687 @default.
• W2594861736 creator A5031050958 @default.
• W2594861736 creator A5034005852 @default.
• W2594861736 creator A5037541807 @default.
• W2594861736 creator A5051884991 @default.
• W2594861736 creator A5057287090 @default.
• W2594861736 creator A5060108045 @default.
• W2594861736 creator A5072238075 @default.
• W2594861736 creator A5082102746 @default.
• W2594861736 creator A5089861374 @default.
• W2594861736 date "2017-05-10" @default.
• W2594861736 modified "2023-10-13" @default.
• W2594861736 title "Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR)" @default.
• W2594861736 cites W1832855151 @default.
• W2594861736 cites W1987616570 @default.
• W2594861736 cites W1994648461 @default.
• W2594861736 cites W2005829193 @default.
• W2594861736 cites W2018530122 @default.
• W2594861736 cites W2019836798 @default.
• W2594861736 cites W2026656096 @default.
• W2594861736 cites W2034843329 @default.
• W2594861736 cites W2044905105 @default.
• W2594861736 cites W2045634223 @default.
• W2594861736 cites W2049659810 @default.
• W2594861736 cites W2054438658 @default.
• W2594861736 cites W2061675342 @default.
• W2594861736 cites W2066135808 @default.
• W2594861736 cites W2068639674 @default.
• W2594861736 cites W2071625393 @default.
• W2594861736 cites W2097254028 @default.
• W2594861736 cites W2099711117 @default.
• W2594861736 cites W2104450983 @default.
• W2594861736 cites W2107102367 @default.
• W2594861736 cites W2121251645 @default.
• W2594861736 cites W2125871683 @default.
• W2594861736 cites W2132556766 @default.
• W2594861736 cites W2140692703 @default.
• W2594861736 cites W2141486573 @default.
• W2594861736 cites W2148303621 @default.
• W2594861736 cites W2167854858 @default.
• W2594861736 cites W2200285648 @default.
• W2594861736 cites W2223666951 @default.
• W2594861736 cites W2235801599 @default.
• W2594861736 cites W2262470417 @default.
• W2594861736 cites W2268256841 @default.
• W2594861736 cites W2312006805 @default.
• W2594861736 cites W2318626491 @default.
• W2594861736 cites W2328283778 @default.
• W2594861736 cites W2531272164 @default.
• W2594861736 cites W2586885021 @default.
• W2594861736 cites W2589907109 @default.
• W2594861736 cites W3140388327 @default.
• W2594861736 cites W4362223089 @default.
• W2594861736 cites W788737191 @default.
• W2594861736 doi "https://doi.org/10.1200/jco.2016.69.7391" @default.
• W2594861736 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5455702" @default.
• W2594861736 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28240967" @default.
• W2594861736 hasPublicationYear "2017" @default.
• W2594861736 type Work @default.
• W2594861736 sameAs 2594861736 @default.
• W2594861736 citedByCount "81" @default.
• W2594861736 countsByYear W25948617362017 @default.
• W2594861736 countsByYear W25948617362018 @default.
• W2594861736 countsByYear W25948617362019 @default.
• W2594861736 countsByYear W25948617362020 @default.
• W2594861736 countsByYear W25948617362021 @default.
• W2594861736 countsByYear W25948617362022 @default.
• W2594861736 countsByYear W25948617362023 @default.
• W2594861736 crossrefType "journal-article" @default.
• W2594861736 hasAuthorship W2594861736A5002055690 @default.
• W2594861736 hasAuthorship W2594861736A5005554940 @default.
• W2594861736 hasAuthorship W2594861736A5016828265 @default.
• W2594861736 hasAuthorship W2594861736A5019646420 @default.
• W2594861736 hasAuthorship W2594861736A5023774687 @default.
• W2594861736 hasAuthorship W2594861736A5031050958 @default.
• W2594861736 hasAuthorship W2594861736A5034005852 @default.
• W2594861736 hasAuthorship W2594861736A5037541807 @default.
• W2594861736 hasAuthorship W2594861736A5051884991 @default.
• W2594861736 hasAuthorship W2594861736A5057287090 @default.
• W2594861736 hasAuthorship W2594861736A5060108045 @default.
• W2594861736 hasAuthorship W2594861736A5072238075 @default.
• W2594861736 hasAuthorship W2594861736A5082102746 @default.
• W2594861736 hasAuthorship W2594861736A5089861374 @default.
• W2594861736 hasBestOaLocation W25948617361 @default.
• W2594861736 hasConcept C126322002 @default.
• W2594861736 hasConcept C141071460 @default.
• W2594861736 hasConcept C142724271 @default.
• W2594861736 hasConcept C143998085 @default.
• W2594861736 hasConcept C168563851 @default.
• W2594861736 hasConcept C203092338 @default.
• W2594861736 hasConcept C204787440 @default.
• W2594861736 hasConcept C207103383 @default.

• next